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 We neglect primary HIV prevention at our peril
Inspired by a steady decline in new HIV infections and 
AIDS-related deaths, the sustainable development goals 
call for ending the AIDS epidemic as a public health 
threat by 2030. However, the world is not on track to 
end the epidemic. In particular, the pace at which new 
HIV infections are declining is substantially slower than 
the fall in AIDS-related deaths, and epidemic control 
remains out of reach. In 2015, the estimated number 
of new HIV infections in adults (1·9 million worldwide) 
was no fewer than in 2010.1 Unless the decline in new 
HIV infections is accelerated, a rebound of the epidemic 
is likely, with potentially catastrophic consequences for 
the communities most vulnerable to HIV.
Although antiretroviral therapy (ART) is powerfully 
eﬀ ective in reducing the risk of HIV transmission,2 
HIV transmission will persist even with achievement 
of the ambitious UNAIDS 90-90-90 target for ART.2 
Only by combining scaled up ART with substantially 
more eﬀ ective prevention of HIV acquisition will 
the decline in the global HIV burden accelerate. The 
urgency of strengthening HIV prevention is emphasised 
by demographic realities, as the proportion of the 
population younger than age 15 exceeds 40% in all but 
eight countries in sub-Saharan Africa.3 In the coming 
years, as this especially large cohort of young people 
enters young adolescence and young adulthood, when 
HIV acquisition risks are greatest, failing to strengthen 
primary HIV prevention will undermine the beneﬁ ts of 
treatment.3 In the high-burden countries of eastern and 
southern Africa, this demographic bulge poses particular 
risks of HIV acquisition for adolescent girls and young 
women.
Eﬀ orts to prevent new HIV infections early in the 
epidemic were stymied by a shortage of validated 
data on the sources of new infections and scaleable 
prevention approaches, but this is no longer the case. 
Scientiﬁ c ﬁ ndings over the past decade have greatly 
expanded the evidence base for HIV prevention. 
As Krishnaratne and colleagues observe,4 clear 
evidence exists of eﬃ  cacy for voluntary medical male 
circumcision (VMMC), pre-exposure antiretroviral 
prophylaxis (PrEP), HIV treatment as prevention, 
and other biomedical approaches, as well as strong 
evidentiary support for interventions to increase 
the supply of condoms, clean needles, and other 
prevention measures.4,5 Evidence strongly indicates 
that the most eﬀ ective approach to reducing the 
number of new HIV infections is a combination of 
biomedical, behavioural, and structural interventions 
that both reduces vulnerability to HIV acquisition and 
accelerates uptake of key prevention methods. 
Despite improvements in HIV prevention science 
over the past decade, we have yet to see a suﬃ  cient 
decline in new HIV infections. As Dehne and coauthors6 
explain, current prevention eﬀ orts suﬀ er from several 
weaknesses, including chronic underfunding, variable 
quality of programme design, the failure to bring 
interventions to scale, and poor or non-existent 
monitoring of outcomes. A much stronger, more 
rigorous approach to HIV prevention, with clearer 
monitoring and accountability, focused on a single 
agreed target for reducing new infections, is needed 
to accelerate the decline in the global HIV burden. 
Modelling by Smith and co-workers7 indicate that 
scale-up of existing interventions would strongly 
accelerate the decline in HIV incidence, but that the 
public health impact of existing approaches would be 
magniﬁ ed by the development and complementary 
use of newer, easier-to-use technologies that rely less 
on individual adherence. Synergistic combination of 
diverse approaches, including structural interventions, 
is likely to optimise prevention outcomes.
Where HIV services have succeeded, programme 
designers, implementers, and evaluators have used 
service cascades to clarify key programmatic elements, 
highlight areas where gaps, or leaks, in the cascade 
occur, and inform eﬀ orts to adapt programmatic 
design and approaches to improve performance and 
outcomes. For example, eﬀ orts to prevent new HIV 
infections among children have long beneﬁ ted from 
the routine use of data-based service cascades.8,9 As 
the coverage and performance of services to prevent 
mother-to-child HIV transmission (PMTCT) have 
improved, the health beneﬁ ts for children have 
increased, with 45% fewer children newly infected in 
2014 compared with 2009.10 Indeed, PMTCT eﬀ orts, 
informed by strong data collection and programme 
monitoring, represent what is arguably the single most 
important prevention achievement in the history of 
the epidemic.
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Cascades have also transformed the HIV treatment 
agenda. The earliest push to scale up HIV treatment 
focused almost exclusively on the number of people 
initiating ART; treatment eﬀ orts more recently 
have routinely monitored outcomes along the HIV 
treatment cascade, culminating in the ultimate 
outcome of viral suppression.11 A cascade approach 
is now the agreed framework for planning and 
monitoring HIV treatment eﬀ orts, as reﬂ ected in the 
UNAIDS 90-90-90 target.
Cascades have clear beneﬁ ts, oﬀ ering insights to 
national decision makers and international donors 
about the return on their HIV investments and how 
best to allocate resources to close leaks in the cascade 
and improve ultimate outcomes. A cascade approach 
also oﬀ ers advantages at a project level, enabling 
implementers to identify and address bottlenecks and 
improve performance over time.
Although cascades have been applied most 
prominently to what are often thought of as 
biomedical inter ventions, they also serve to highlight 
the behavioural and structural factors that inﬂ uence 
uptake of and adherence to biomedical regimens, as 
described by Hargreaves and coauthors.12 These include 
such issues as acceptability, demand, perceived eﬃ  cacy 
for self-care, stigma and discrimination, and life 
challenges (eg, poverty, housing instability, violence) 
that may impede an individual’s ability to adhere to 
prevention regimens.
Garnett and colleagues13 applied a cascade approach 
to a cluster of validated prevention approaches 
with data in east Zimbabwe to assess the value of 
this approach. This exercise shows the feasibility 
of populating an HIV prevention cascade with 
population-level data to assess the ultimate impact of 
a prevention intervention and to identify the factors 
that may prevent the intervention from being used 
to full eﬀ ect. In the case of VMMC, for example, the 
cascade analysis determined that a low perception 
of risk prevents many men who could beneﬁ t from 
VMMC from accessing the service. This suggests that 
the health impact of VMMC is unlikely to be maximised 
without complementary interventions to better 
motivate men to seek voluntary circumcision.
In HIV prevention eﬀ orts, the role of evidence-
driven programme design, routine data collection and 
analysis, a clear focus on an agreed target for reducing 
new infections, and rigorous evaluation of outcomes 
must markedly increase. As the articles in this issue 
illustrate, intervention-speciﬁ c service cascades oﬀ er 
an important avenue to improve the soundness and 
eﬀ ect of prevention programmes. Our call to enhance 
the rigour of prevention programming is urgent, as 
hopes for meeting our ambitious global goals will 
only be achieved if treatment-associated reductions 
in HIV transmission are matched by an equally robust, 
sustained reduction in HIV acquisition.
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